Loading data for MGTX — first visit, this takes a few seconds.
MeiraGTx (MGTX)
: MGTX
· Echtzeitkurs · USD
n/a
n/a (n/a)
Zum Schluss: Invalid Date
MeiraGTx (MGTX) Stock Price, Analysis & Data
Keine Daten verfügbar
| Geld | n/a |
| Marktkapitalisierung | n/a |
| Umsatz (TTM) | 397.5 Mio |
| Nettogewinn (TTM) | 78.98 Mio |
| Beta | 1.25 |
| EPS (ttm) | n/a |
| KGV (TTM) | n/a |
| Forward-KGV | -10.41 |
| KBV (TTM) | 6.32 |
| KUV (TTM) | 3.50 |
| Earnings Date | n/a |
| Brief | n/a |
| Volumen | NaN |
| Ø Vol. (20D) | n/a |
| Eröffnung | n/a |
| Vortagesschluss | n/a |
| Tagesspanne | n/a - n/a |
| 52-Wk Range | n/a - n/a |
| Analyst | n/a |
| Kursziel | n/a |
| Dividenden | n/a |
| Ex-Dividenden-Datum | n/a |
Über MGTX
MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GA...
Branche Biotechnology
Sektor Healthcare
IPO Datum Jun 8, 2018
Mitarbeiter 393
Börse NasdaqGS
Tickersymbol MGTX
Website https://www.meiragtx.com
Finanzielle Entwicklung
Im Jahr 2025 betrug der Umsatz von MeiraGTx 81.39 Mio, ein Anstieg von 144.57% im Vergleich zum Vorjahr (33.28 Mio). Der Gewinn lag bei -114.2 Mio, ein Rückgang von -22.73 %.
Finanzberichte